Anti-fibrotic effects of class I HDAC inhibitor, mocetinostat is associated with IL-6/stat3 signaling in ischemic heart failure

International Journal of Molecular Sciences

Volumn 16, Issue 5, 2015, Pages 11482-11499

  Nural Guvener, Hikmet ^a   Zakharova, Liudmila ^a   Feehery, Lorraine ^a   Sljukic, Snjezana ^a   Gaballa, Mohamed ^a  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Cardiac fibrosis; Congestive heart failure; HDAC; Mocetinostat; Myocardial infarction

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; INTERLEUKIN 6; MOCETINOSTAT; STAT3 PROTEIN; THY 1 ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; BENZAMIDE DERIVATIVE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FIBROBLAST; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; IMMUNOHISTOCHEMISTRY; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION; GENETICS; HEART FAILURE; HEART VENTRICLE FUNCTION; METABOLISM; PATHOLOGY; SCAR; SIGNAL TRANSDUCTION;

ANIMALIA; RATTUS;

ANIMALS; BENZAMIDES; CICATRIX; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE MODELS, ANIMAL; FIBROBLASTS; FIBRONECTINS; FIBROSIS; GENE EXPRESSION; HEART FAILURE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; INTERLEUKIN-6; MYOCARDIAL ISCHEMIA; PYRIMIDINES; RATS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VENTRICULAR FUNCTION;

EID: 84930615677     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160511482     Document Type: Article

References (39)

1. Squires, C.E.; Escobar, G.P.; Payne, J.F.; Leonardi, R.A.; Goshorn, D.K.; Sheats, N.J.; Mains, I.M.; Mingoia, J.T.; Flack, E.C.; Lindsey, M.L. Altered fibroblast function following myocardial infarction. J. Mol. Cell. Cardiol. 2005, 39, 699-707.
2. Van den Borne, S.W.; Diez, J.; Blankesteijn, W.M.; Verjans, J.; Hofstra, L.; Narula, J. Myocardial remodeling after infarction: The role of myofibroblasts. Nat. Rev. Cardiol. 2010, 7, 30-37.
3. Porter, K.E.; Turner, N.A. Cardiac fibroblasts: At the heart of myocardial remodeling. Pharmacol. Ther. 2009, 123, 255-278.
4. Iyer, A.; Fenning, A.; Lim, J.; Le, G.T.; Reid, R.C.; Halili, M.A.; Fairlie, D.P.; Brown, L. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br. J. Pharmacol. 2010, 159, 1408-1417.
5. Kao, Y.H.; Liou, J.P.; Chung, C.C.; Lien, G.S.; Kuo, C.C.; Chen, S.A.; Chen, Y.J. Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure. Int. J. Cardiol. 2013, 168, 4178-4183.
6. Kee, H.J.; Sohn, I.S.; Nam, K.I.; Park, J.E.; Qian, Y.R.; Yin, Z.; Ahn, Y.; Jeong, M.H.; Bang, Y.J.; Kim, N.; et al. Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding. Circulation 2006, 113, 51-59.
7. Kong, Y.; Tannous, P.; Lu, G.; Berenji, K.; Rothermel, B.A.; Olson, E.N.; Hill, J.A. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 2006, 113, 2579-2588.
8. + cardiac myofibroblast activation Fibrogenesis. Tissue Repair 2014, 7, 10.
9. Williams, S.M.; Golden-Mason, L.; Ferguson, B.S.; Douglas, K.B.; Cavasin, M.A.; Demos-Davies, K.; Yeager, M.E.; Stenmark, K.R.; McKinsey, T.A. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J. Mol. Cell. Cardiol. 2013, 67, 112-125.
10. Lee, T.M.; Lin, M.S.; Chang, N.C. Inhibition of histone deacetylase on ventricular remodeling in infarcted rats American journal of physiology. Heart Circ. Physiol. 2007, 293, H968-H977.
11. Kook, H.; Lepore, J.J.; Gitler, A.D.; Lu, M.M.; Wing-Man Yung, W.; Mackay, J.; Zhou, R.; Ferrari, V.; Gruber, P.; Epstein, J.A. Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop. J. Clin. Investig. 2003, 112, 863-871.
12. Zhang, L.; Chen, B.; Zhao, Y.; Dubielecka, P.M.; Wei, L.; Qin, G.J.; Chin, Y.E.; Wang, Y.; Zhao, T.C. Inhibition of histone deacetylase-induced myocardial repair is mediated by c-kit in infarcted hearts. J. Biol. Chem. 2012, 287, 39338-39348.
13. Zhang, L.; Qin, X.; Zhao, Y.; Fast, L.; Zhuang, S.; Liu, P.; Cheng, G.; Zhao, T.C. Inhibition of histone deacetylases preserves myocardial performance and prevents cardiac remodeling through stimulation of endogenous angiomyogenesis. J. Pharmacol. Exp. Ther. 2012, 341, 285-293.
14. Kapoun, A.M.; Liang, F.; OʼYoung, G.; Damm, D.L.; Quon, D.; White, R.T.; Munson, K.; Lam, A.; Schreiner, G.F.; Protter, A.A. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: Fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ. Res. 2004, 94, 453-461.
15. Pathak, M.; Sarkar, S.; Vellaichamy, E.; Sen, S. Role of myocytes in myocardial collagen production. Hypertension 2001, 37, 833-840.
16. Daniels, A.; van Bilsen, M.; Goldschmeding, R.; van der Vusse, G.J.; van Nieuwenhoven, F.A. Connective tissue growth factor and cardiac fibrosis. Acta Physiol. 2009, 195, 321-338.
17. Koitabashi, N.; Arai, M.; Kogure, S.; Niwano, K.; Watanabe, A.; Aoki, Y.; Maeno, T.; Nishida, T.; Kubota, S.; Takigawa, M.; et al. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007, 49, 1120-1127.
18. Haugen, E.; Gan, L.M.; Isic, A.; Skommevik, T.; Fu, M. Increased interleukin-6 but not tumour necrosis factor-alpha predicts mortality in the population of elderly heart failure patients. Exp. Clin. Cardiol. 2008, 13, 19-24.
19. Hirota, H.; Izumi, M.; Hamaguchi, T.; Sugiyama, S.; Murakami, E.; Kunisada, K.; Fujio, Y.; Oshima, Y.; Nakaoka, Y.; Yamauchi-Takihara, K. Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure. Heart Vessel. 2004, 19, 237-241.
20. Wollert, K.C.; Drexler, H. The role of interleukin-6 in the failing heart. Heart Fail. Rev. 2001, 6, 95-103.
21. Kurdi, M.; Booz, G.W. Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin-6-type cytokine signaling. J. Cardiovasc. Pharmacol. 2007, 50, 126-141.
22. Fischer, P.; Hilfiker-Kleiner, D. Survival pathways in hypertrophy and heart failure: The gp130-STAT3 axis. Basic Res. Cardiol. 2007, 102, 279-297.
23. Hilfiker-Kleiner, D.; Shukla, P.; Klein, G.; Schaefer, A.; Stapel, B.; Hoch, M.; Muller, W.; Scherr, M.; Theilmeier, G.; Ernst, M.; et al. Continuous glycoprotein-130-mediated signal transducer and activator of transcription-3 activation promotes inflammation, left ventricular rupture, and adverse outcome in subacute myocardial infarction. Circulation 2010, 122, 145-155.
24. Pang, M.; Kothapally, J.; Mao, H.; Tolbert, E.; Ponnusamy, M.; Chin, Y.E.; Zhuang, S. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am. J. Physiol. Ren. Physiol. 2009, 297, F996-F1005.
25. Glauben, R.; Sonnenberg, E.; Wetzel, M.; Mascagni, P.; Siegmund, B. Histone deacetylase inhibitors modulate interleukin 6-dependent CD4+ T cell polarization in vitro and in vivo. J. Biol. Chem. 2014, 289, 6142-6151.
26. Zakharova, L.; Mastroeni, D.; Mutlu, N.; Molina, M.; Goldman, S.; Diethrich, E.; Transplantation of cardiac progenitor cell sheet onto infarcted heart promotes cardiogenesis and improves function. Cardiovasc. Res. 2010, 87, 40-49.
27. Condorelli, F.; Gnemmi, I.; Vallario, A.; Genazzani, A.A.; Canonico, P.L. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br. J. Pharmacol. 2008, 153, 657-668.
28. Mir, S.A.; Chatterjee, A.; Mitra, A.; Pathak, K.; Mahata, S.K.; Sarkar, S. Inhibition of signal transducer and activator of transcription 3 (STAT3) attenuates interleukin-6 (IL-6)-induced collagen synthesis and resultant hypertrophy in rat heart. J. Biol. Chem. 2012, 287, 2666-2677.
29. Ma, F.; Li, Y.; Jia, L.; Han, Y.; Cheng, J.; Li, H.; Qi, Y.; Du, J. Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF beta/Smad activation and cardiac fibrosis induced by angiotensin II. PLoS ONE 2012, 7, e35144.
30. Fredj, S.; Bescond, J.; Louault, C.; Delwail, A.; Lecron, J.C.; Potreau, D. Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. J. Cell. Physiol. 2005, 204, 428-436.
31. Melendez, G.C.; McLarty, J.L.; Levick, S.P.; Du, Y.; Janicki, J.S.; Brower, G.L. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 2010, 56, 225-231.
32. Sarkar, S.; Vellaichamy, E.; Young, D.; Sen, S. Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: Role of myocytes. Am. J. Physiol. Heart Circ. Physiol. 2004, 287, H107-H117.
33. Mandala, T.; Bhowmik, A.; Chatterjee, A.; Chatterjee, U.; Chatterjee, S.; Ghosh, M.K. Reduced phosphorylation of Stat3 at Ser-727 mediated by casein kinase 2—Protein phosphatase 2A enhances Stat3 Tyr-705 induced tumorigenic potential of glioma cells. Cell. Signal. 2014, 26, 1725-1734.
34. Hilfiker-Kleiner, D.; Hilfiker, A.; Fuchs, M.; Kaminski, K.; Schaefer, A.; Schieffer, B.; Hillmer, A.; Schmiedl, A.; Ding, Z.; Podewski, E.; et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ. Res. 2004, 95, 187-195.
35. Oshima, Y.; Fujio, Y.; Nakanishi, T.; Itoh, N.; Yamamoto, Y.; Negoro, S.; Tanaka, K.; Kishimoto, T.; Kawase, I.; Azuma, J. STAT3 mediates cardioprotection against ischemia/reperfusion injury through metallothionein induction in the heart. Cardiovasc. Res. 2005, 65, 428-435.
36. McGaffin, K.R.; Moravec, C.S.; McTiernan, C.F. Leptin signaling in the failing and mechanically unloaded human heart. Circ. Heart Fail. 2009, 2, 676-683.
37. Gaballa, M.A.; Raya, T.E.; Goldman, S. Large artery remodeling after myocardial infarction. Am. J. Physiol. 1995, 268, H2092-H2103.
38. Gaballa, M.A.; Goldman, S. Gene transfer of endothelial nitric oxide isoform decreases rat hindlimb vascular resistance in vivo. Hum. Gene Ther. 2000, 11, 1637-1646.
39. Hadi, A.M.; Mouchaers, K.T.; Schalij, I.; Grunberg, K.; Meijer, G.A.; Vonk-Noordegraaf, A.; van der Laarse, W.J.; Belien, J.A. Rapid quantification of myocardial fibrosis: A new macro-based automated analysis. Cell Oncol. 2011, 34, 343-354.